We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
+31.05%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$3.42B
AUM Growth
+$931M
Cap. Flow
+$320M
Cap. Flow %
9.36%
Top 10 Hldgs %
45.63%
Holding
88
New
10
Increased
35
Reduced
24
Closed
6
Avg Time Held
5.2 quarters
Top 10 Avg Time Held
5 quarters
Top 20 Avg Time Held
5.3 quarters

Top Buys

Rank Stock Value
1
FOLD icon
Amicus Therapeutics
FOLD
+$138M
2
BIIB icon
Biogen
BIIB
+$52.1M
3
CELG
Celgene Corp
CELG
+$46.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$37.1M
5
ALGN icon
Align Technology
ALGN
+$34.2M

Top Sells

Rank Stock Value
1
ARRY icon
Array Biopharma Inc
ARRY
+$114M
2
CI icon
Cigna
CI
+$50M
3
MDT icon
Medtronic
MDT
+$38.2M
4
CVS icon
CVS Health
CVS
+$25.1M
5
NITE icon
Nightstar Therapeutics plc American Depositary Shares
NITE
+$20.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.09%
2 Financials 2.23%
3 Miscellaneous 1.67%
4 Energy 0.01%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ARRY icon
1
DELISTED
Array Biopharma Inc
ARRY
$267M 7.83%
10,970,518
-5,488,610
-33% -$114M
2013 Q2
23 quarters
FOLD icon
2
DELISTED
Amicus Therapeutics
FOLD
$267M 7.81%
19,616,062
+11,292,845
+136% +$138M
2013 Q2
23 quarters
FATE icon
3
Fate Therapeutics
FATE
$229M
$182M 5.33%
10,359,666
– –
2015 Q2
15 quarters
ATRA icon
4
Atara Biotherapeutics
ATRA
$94.5M
$178M 5.22%
179,417
+2,832
+2% +$2.63M
2014 Q4
17 quarters
ARGX icon
5
argenx
ARGX
$51.9B
$127M 3.72%
1,019,061
+58,100
+6% +$6.83M
2017 Q4
5 quarters
CLVS
6
DELISTED
Clovis Oncology, Inc.
CLVS
$113M 3.31%
4,563,929
+503,400
+12% +$12.6M
2018 Q2
3 quarters
ALDR
7
DELISTED
Alder Biopharmaceuticals
ALDR
$113M 3.29%
8,244,896
+1,739,130
+27% +$22.5M
2016 Q3
10 quarters
WVE icon
8
Wave Life Sciences
WVE
$599M
$110M 3.22%
2,831,507
+593,900
+27% +$24.1M
2015 Q4
13 quarters
BOLD icon
9
DELISTED
Audentes Therapeutics, Inc
BOLD
$107M 3.12%
2,735,267
+433,600
+19% +$12.4M
2016 Q3
10 quarters
EPZM
10
DELISTED
Epizyme, Inc
EPZM
$95.3M 2.79%
7,694,020
+1,056,742
+16% +$11.8M
2017 Q3
6 quarters
XNCR icon
11
Xencor
XNCR
$1.79B
$94.3M 2.76%
3,036,603
-48,100
-2% -$1.6M
2016 Q4
9 quarters
WMGI
12
DELISTED
Wright Medical Group Inc
WMGI
$90.4M 2.64%
2,874,100
+336,800
+13% +$10.2M
2018 Q3
2 quarters
IFRX icon
13
InflaRx
IFRX
$217M
$82.5M 2.41%
2,182,638
+147,238
+7% +$5.49M
2017 Q4
5 quarters
RGNX icon
14
Regenxbio
RGNX
$457M
$81.4M 2.38%
1,420,342
+65,600
+5% +$3.25M
2017 Q1
8 quarters
QURE icon
15
uniQure
QURE
$1.41B
$78M 2.28%
1,307,522
+4,100
+0.3% +$183K
2018 Q2
3 quarters
BMY icon
16
Bristol-Myers Squibb
BMY
$120B
$76.3M 2.23%
1,599,700
+745,000
+87% +$37.1M
2018 Q4
1 quarter
EHTH icon
17
eHealth
EHTH
$19.3M
$76.2M 2.23%
1,222,405
+131,010
+12% +$7.22M
2016 Q4
9 quarters
ALLK icon
18
DELISTED
Allakos
ALLK
$74.3M 2.17%
1,834,410
+135,762
+8% +$5.49M
2018 Q3
2 quarters
LIVN icon
19
LivaNova
LIVN
$4.17B
$56.7M 1.66%
582,687
+67,700
+13% +$6.32M
2017 Q2
7 quarters
TNDM icon
20
Tandem Diabetes Care
TNDM
$1.13B
$54.4M 1.59%
855,932
-183,818
-18% -$9.66M
2018 Q3
2 quarters
ELV icon
21
Elevance Health
ELV
$91.7B
$50.7M 1.48%
176,700
+61,200
+53% +$17.7M
2018 Q2
3 quarters
CELG
22
DELISTED
Celgene Corp
CELG
$50.5M 1.48%
+535,700
New +$46.9M
2019 Q1
0 quarters
TEVA icon
23
Teva Pharmaceutical Industries Limited
TEVA
$48.5B
$49.3M 1.44%
3,147,000
+1,318,100
+72% +$23.2M
2018 Q4
1 quarter
PEN icon
24
Penumbra
PEN
$12.6B
$47.5M 1.39%
323,170
+177,562
+122% +$25.4M
2015 Q3
14 quarters
ALGN icon
25
Align Technology
ALGN
$10.1B
$40.7M 1.19%
+143,200
New +$34.2M
2019 Q1
0 quarters
1
2 3 4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q1 2019 Portfolio in Review

As of Q1 2019, Redmile Group held 88 positions worth $3.42B, up 37% from $2.49B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Redmile Group deployed $320M of net new capital in Q1 2019, opening 10 new positions and adding to 35 existing holdings. Its largest new stake was Biogen: 165,300 shares worth $39.1M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Financials and Miscellaneous.

On the sell side, the largest reduction was Array Biopharma Inc, an estimated $114M trimmed.

  • Redmile Group's largest Q1 2019 buy was Biogen: 165,300 shares worth $39.1M.
  • Redmile Group added most to Amicus Therapeutics in Q1 2019, an estimated $138M increase.
  • Redmile Group's biggest Q1 2019 reduction was Array Biopharma Inc, cutting an estimated $114M.
  • Redmile Group fully exited Medtronic in Q1 2019, selling an estimated $38.2M.
  • Redmile Group's ten largest holdings make up 46% of its $3.42B portfolio in Q1 2019.
  • Redmile Group opened 10 new positions and closed 6 in Q1 2019.
  • Redmile Group's portfolio value rose 37% quarter-over-quarter to $3.42B.

Based on Redmile Group's 13F filing for Q1 2019, filed 15 May 2019.